Assessing the Actual Risk of Eating Disorders Associated with GLP-1 Medications
-
By
-
Theresa Gaffney
-
April 27, 2026
-
Clinical Scorecard: Assessing the Actual Risk of Eating Disorders Associated with GLP-1 Medications
At a Glance
| Category | Detail |
|---|
| Condition | Eating Disorders |
| Key Mechanisms | Potential development of eating disorders in patients using GLP-1 medications. |
| Target Population | Individuals prescribed GLP-1 weight loss medications. |
| Care Setting | Primary care and obesity management clinics. |
Key Highlights
- 1.28% of over 60,000 GLP-1 users diagnosed with an eating disorder within two years.
- Potential for over 420,000 Americans to develop eating disorders if one in eight takes GLP-1s.
- Need for screening for eating disorders before prescribing GLP-1 medications.
- Calls for more research on the risks and treatment implications of GLP-1s related to eating disorders.
Guideline-Based Recommendations
Diagnosis
- Screen patients for eating disorders prior to prescribing GLP-1 medications.
Management
- Monitor patients for signs of eating disorders during treatment with GLP-1 medications.
Monitoring & Follow-up
- Regular follow-up assessments to evaluate mental health and eating behaviors.
Risks
- Increased risk of eating disorders associated with GLP-1 medication use.
Patient & Prescribing Data
Individuals seeking weight loss solutions through GLP-1 medications.
Understanding the mechanistic overlap between obesity and anorexia is crucial for treatment.
Clinical Best Practices
- Implement routine screening for eating disorders in patients prescribed GLP-1s.
- Educate patients about the potential risks of eating disorders associated with GLP-1 medications.
References
